ACCCBUZZ BLOG

Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.

At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.

Nationally, approximately 1 in 5 patients who qualify for CAR T-cell therapy never receive it due to geographic distance, travel burden, or limited availability at specialized inpatient centers. Recognizing a critical need in its community, Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana, launched the region’s first fully outpatient CAR T-cell therapy program for select blood cancers, fundamentally redefining how advanced cellular therapies can be delivered safely outside of a hospital setting and earning the program a 2026 ACCC Innovator Award.

To better reach its patients living in rural communities throughout Georgia with targeted interventions, 2026 ACCC Innovator Award winner Winship Cancer Institute developed an Embedded Community Staff model, which leverages the experiential knowledge of local community members.

2026 ACCC Innovator Award Winner UNC Lineberger Comprehensive Cancer Center noticed a common pain point among patients who received oncolytic virus treatment for advanced melanoma: time spent in appointments. To minimize the need for multiple lengthy appointments, the center developed a pharmacist-led strategy that utilized virtual visits and premixing doses prior to in-person visits.

In a recent article from Oncology Issues, authors conducted a systematic literature review and found that two main drivers of care disparities exist for transgender and nonbinary individuals with cancer: rigid binary gender frameworks and gaps in mental health care.

2026 ACCC Innovator Award Winner St. Luke's Cancer Institute noticed a significant administrative burden being placed on providers to review medical necessity validation for complex oncology therapies. To address the resulting rise in peer-to-peer requirements, delays in care, and pre-service denials, the team designed and implemented a new Clinical Documentation Integrity Registered Nurse role.

ACCC launched its Precision Medicine Stewardship Program to highlight institutions that have successfully built the infrastructure, workflows, and leadership models needed to deliver precision medicine at scale. TriHealth Cancer and Blood Institute in Cincinnati, Ohio, offers a compelling example of what it takes to move from aspiration to execution.

Although patients with relapsed or refractory multiple myeloma now have more treatment options than ever, their journeys are often complex. As clinicians consider when to introduce newer therapies such as bispecific antibodies, they must account for prior treatments, treatment-related toxicities, and comorbidities that may impact treatment decisions.

Each year, the NCCN State Oncology Society Forum is thoughtfully organized to foster meaningful collaboration and forge common bonds to advance dignity and fair access to cancer care. In this blog, Sean T. McCarson shares key insights from stakeholders across the oncology policy landscape at this year's meeting.

The latest issue of Oncology Issues features key insights from the inaugural ACCC Leadership Summit, strategies to adjust to rising patient volumes and workforce strain, advanced practice leadership models, and more.

In the third in a series of multidisciplinary consensus-building roundtables, ACCC and its partners explored ways to bridge the gap between community oncology programs and authorized treatment centers offering CAR T for patients with multiple myeloma.

In a recent conversation with ACCC, Kevan Simms, MBA, PMP, Assistant Vice President of Precision Medicine at Ochsner Health, shared how his organization is building a scalable stewardship model that not only improves current oncology care but also prepares for the future.

In a recent conversation with ACCC, DiMe Associate Program Director Ian Miller discussed what responsible AI adoption looks like in practice, particularly for organizations early in their AI journey and seeking clearer guidance on how to evaluate, prioritize, and implement these tools.

In the recent NCCN policy summit "Health Literacy in the Cancer Care Digital Age," speakers and panelists discussed how best to communicate with patients and foster the responsible use of emerging technologies, with a strong focus on shared decision-making.

In her recent appearance on Sanofi’s Patient Advocacy Voices podcast, ACCC Executive Director Meagan O’Neill discusses the operational gaps that delay access to cancer care, structural barriers that impact patient outcomes, and ACCC’s mission to supply a “how to” approach in bringing breakthrough science to cancer programs in the form of practical solutions.

A recent discussion between ACCC and Highlands Oncology centered on how artificial intelligence can be implemented thoughtfully in cancer care to support clinicians and operations without compromising clinical judgement or patient care.

Small Cell SMASHERS was founded in 2023 as a patient-centered advocacy and education community designed to challenge long-standing narratives about small cell lung cancer and restore a sense of voice, connection, and hope for patients and their loved ones.

ACCCBuzz spoke with Fox Chase Cancer Center to learn more about its partnership with Omniscope, a leader in advanced molecular profiling technology, in hopes of developing an assay that accurately predicts which patients will respond well to immunotherapy based on the presence of certain T-cell clones.

On Friday, April 17, ACCC welcomed oncology leaders from around the country to Washington, DC for the inaugural ACCC Leadership Summit, a forum designed for executive-level decision-makers to engage in strategic dialogue, peer-to-peer exchange, and actionable insights at the highest level of oncology leadership.

During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.

From Ghana to Orlando, experts across the multidisciplinary care team share how they are expanding access to clinical trials and supportive care services and improving quality of life for their patients as a result in this Oncology Issues. Read on for a preview of this issue’s articles and dive deeper to learn from colleagues across the country and the globe.

On day 1 of the NCCN 2026 Annual Conference, attendees heard from experts on the unique issues young adults with cancer face during and post-treatment, advances in treating gastrointestinal cancers, evolving therapies in skin cancers, and novel approaches to treating blood cancers.

ACCCBuzz interviewed leadership from the National Association of Veterans’ Research and Education Foundations to better understand the current clinical and operational barriers Veterans face in accessing clinical trials and the progress being made to address them.